BLOG

biospace

CEL-SCI, Jazz, CARsgen, Ascentage and Portage Showcase New Data at ASCO

Westport, Connecticut’s Portage Biotech presented new data Monday from a Phase I/II study of its invariant natural killer T cell (iNKT) agonist PORT-2, which is being tested for the treatment of melanoma and non-small cell lung cancer (NSCLC).